drugset / Trial / NCT04887259
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
NaSequentialOpen-labelTreatment
Summary
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
Timeline
- Start
- 2021-07-12
- Primary completion
- 2023-09-06
- Completion
- 2023-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAVA-051 | Unknown | — | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |